Mannitol in Cerebral Herniation
For impending cerebral herniation, administer mannitol 20% at a dose of 250 mOsm (approximately 0.25-2 g/kg for adults, 1-2 g/kg for pediatric patients) as a 15-20 minute infusion after first controlling secondary brain insults. 111
Dosing Algorithm
Adult Dosing
- Standard dose: 0.25-2 g/kg body weight as 15-25% solution over 30-60 minutes 2
- Optimal approach: 250 mOsm dose infused over 15-20 minutes 11
- Small/debilitated patients: 500 mg/kg 2
Pediatric Dosing
- Standard: 1-2 g/kg body weight OR 30-60 g/m² body surface area over 30-60 minutes 2
Critical Timing and Mechanism
Mannitol works by creating an osmotic gradient across the blood-brain barrier, pulling water into the hypertonic intravascular space. Maximum ICP reduction occurs at 10-15 minutes, with effects lasting 2-4 hours 11. Among three ICP-lowering therapies (mannitol, external ventricular drainage, hyperventilation), only mannitol improved cerebral oxygenation 1.
Evidence-Based Rationale
The 2018 Anaesthesia guidelines provide Grade 1+ (strong) recommendations for mannitol use in threatened herniation, specifically citing signs like mydriasis, anisocoria, or neurological deterioration not attributable to systemic causes 111. This represents the highest quality guideline evidence available.
Mannitol vs. Hypertonic Saline: At equiosmotic doses (~250 mOsm), both agents show comparable efficacy 11. However, a 2024 study found lower ICU mortality with hypertonic saline (45%) versus mannitol (54%) in prehospital TBI patients with mydriasis 3. Despite this, guidelines maintain both as equivalent first-line options.
Dose-Response Considerations
Research demonstrates that ICP reduction is proportional to baseline ICP values (0.64 mmHg decrease per 1 mmHg baseline elevation), not to mannitol dose 4. Historical studies from 1978 showed that 0.25 g/kg was as effective as larger doses (0.5-1 g/kg) for acute ICP reduction 5. This supports using the smallest effective dose to avoid complications.
More recent data suggests 100 g doses provide more durable ICP control than 50 g doses beyond 100 minutes post-administration 6, though both achieve similar initial reductions at 30 minutes.
Critical Safety Monitoring
Mandatory monitoring includes:
- Fluid balance (mannitol causes osmotic diuresis requiring volume replacement) 11
- Serum sodium and chloride levels 1
- Serum osmolality (aim for ≥10 mOsm increase for ICP effect) 5
- Renal function (avoid in established anuria) 2
- Cardiovascular status (can worsen heart failure) 2
Common Pitfalls to Avoid
Do not use prophylactically: Osmotherapy in patients without documented intracranial hypertension shows no outcome benefit 11
Avoid excessive dosing: Giving more mannitol than needed to reduce ICP below 25 mmHg leads to requirement for larger subsequent doses 7. The concept of "mannitol saturation dosage" exists where effectiveness plateaus 8
Do not use prolonged hyperventilation concurrently: Grade 2- recommendation against prolonged hypocapnia, which worsens neurological outcomes through cerebral ischemia 11
Never use 4% albumin: Grade 2- recommendation against albumin in severe TBI due to increased mortality (41.8% vs 22.2%) 11
Timing matters: Administer after controlling secondary brain insults (hypoxia, hypotension) 11
Administration Technique
- Route: Intravenous only 2
- Rate: 15-20 minute infusion for herniation 11, or 30-60 minutes for standard dosing 2
- Concentration: 15-25% solution 2
- Do not mix with blood products 2
When to Discontinue
Stop mannitol if:
- Renal, cardiac, or pulmonary status worsens 2
- CNS toxicity develops 2
- Serum osmolality exceeds safe thresholds
- Severe dehydration occurs 2
The FDA label specifically contraindicates mannitol in well-established anuria, severe pulmonary edema, active intracranial bleeding (except during craniotomy), and severe dehydration 2.